参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 复旦大学附属华山医院内科学(心血管病学)主...
参考文献: [1] Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. Publish...
A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists. The researchers...
目前,肥胖已成为影响居民健康的重要因素之一,且临床未竟需求明显。希望科学家们在创新疗法开发方面取得更多突破,早日为患者带来安全有效的减肥疗法。 参考资料: [1]Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022 . Retrieved Dec 1, 2022. From网页链接 [2]Amgen Business Review Meeting. Ret...
Amgenplans to initiate Phase 2 testing with a dose-ranging study in early 2023, where long-term effects in an expanded number of patients will be further characterized. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses ...
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. 品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子...
Maridebartcafraglutide有望⽤于肥胖的研究[1][2]。REFERENCES[1].BloomgardenZT.The2023WCIRDC:Obesity[J].JournalofDiabetes,2024,16(4).[2].VéniantMM,etal.AGIPRantagonistconjugatedtoGLP-1analoguespromotesweightlosswithimprovedmetabolicparametersinpreclinicalandphase1settings.NatMetab.2024Feb;6(2):290-...
2月 5 日,安进(Amgen)的研究人员在 Nature Metabolism 期刊发表了题为:A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings 的研究论文,文中表示,安进开发的双特异性分子 AMG 133 每 4 周一剂注射,在第 3 次注射后体...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...
[1] Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. Published online February 5, 2024. doi:10.1038/s42255-023-00966-w...